BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34155628)

  • 21. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
    López-Guillermo A; Cabanillas F; McDonnell TI; McLaughlin P; Smith T; Pugh W; Hagemeister F; Rodríguez MA; Romaguera JE; Younes A; Sarris AH; Preti HA; Lee MS
    Blood; 1999 May; 93(9):3081-7. PubMed ID: 10216105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
    Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
    Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
    Savage KJ; Johnson NA; Ben-Neriah S; Connors JM; Sehn LH; Farinha P; Horsman DE; Gascoyne RD
    Blood; 2009 Oct; 114(17):3533-7. PubMed ID: 19704118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC expression and translocation analyses in low-grade and transformed follicular lymphoma.
    Aukema SM; van Pel R; Nagel I; Bens S; Siebert R; Rosati S; van den Berg E; Bosga-Bouwer AG; Kibbelaar RE; Hoogendoorn M; van Imhoff GW; Kluin-Nelemans HC; Kluin PM; Nijland M
    Histopathology; 2017 Dec; 71(6):960-971. PubMed ID: 28730642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?
    Christie L; Kernohan N; Levison D; Sales M; Cunningham J; Gillespie K; Batstone P; Meiklejohn D; Goodlad J
    Leuk Lymphoma; 2008 Mar; 49(3):470-6. PubMed ID: 18297523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
    Barraclough A; Alzahrani M; Ettrup MS; Bishton M; van Vliet C; Farinha P; Gould C; Birch S; Sehn LH; Sovani V; Ward MS; Augustson B; Biccler J; Connors JM; Scott DW; Gandhi MK; Savage KJ; El-Galaly T; Villa D; Cheah CY
    Blood Adv; 2019 Jul; 3(13):2013-2021. PubMed ID: 31285189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Significance of
    Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
    J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
    Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.
    Federico M; Guglielmi C; Luminari S; Mammi C; Marcheselli L; Gianelli U; Maiorana A; Merli F; Bellei M; Pozzi S; Stelitano C; Lazzaro A; Gobbi PG; Baldini L; Bergantini S; Fregoni V; Brugiatelli M
    Haematologica; 2007 Nov; 92(11):1482-8. PubMed ID: 18024396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
    Federico M; Bellei M; Marcheselli L; Luminari S; Lopez-Guillermo A; Vitolo U; Pro B; Pileri S; Pulsoni A; Soubeyran P; Cortelazzo S; Martinelli G; Martelli M; Rigacci L; Arcaini L; Di Raimondo F; Merli F; Sabattini E; McLaughlin P; Solal-Céligny P
    J Clin Oncol; 2009 Sep; 27(27):4555-62. PubMed ID: 19652063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
    Bachy E; Maurer MJ; Habermann TM; Gelas-Dore B; Maucort-Boulch D; Estell JA; Van den Neste E; Bouabdallah R; Gyan E; Feldman AL; Bargay J; Delmer A; Slager SL; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Ansell SM; Lamy T; Dartigues P; Link BK; Seymour JF; Cerhan JR; Salles G
    Blood; 2018 Jul; 132(1):49-58. PubMed ID: 29666118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review.
    Xu X; Zhang L; Wang Y; Zhang Q; Zhang L; Sun B; Zhang Y
    Int J Clin Exp Pathol; 2013; 6(4):788-94. PubMed ID: 23573328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.
    Ichikawa K; Aritaka N; Ogura K; Hosone M; Ota Y; Sato E; Komatsu N; Hirano T
    Int J Clin Exp Pathol; 2015; 8(6):7559-64. PubMed ID: 26261669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.